EVALUATING THE COST-EFFECTIVENESS OF GLP-1 RECEPTOR AGONISTS FOR THE TREATMENT OF TYPE 2 DIABETES IN THE UK

被引：1
|
作者：
Ashley, D. [1 ]
Vega, G. [1 ]
Hunt, B. [2 ]
Valentine, W. J. [2 ]
机构：
[1] Novo Nordisk Ltd, Gatwick, England
[2] Ossian Hlth Econ & Commun, Basel, Switzerland
来源：
VALUE IN HEALTH | 2015年 / 18卷 / 07期
关键词：
D O I：
10.1016/j.jval.2015.09.2093
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
PDB54
引用
收藏
页码：A606 / A606
页数：1
相关论文
共 50 条
  • [21] Should GLP-1 Receptor Agonists Be the First Line of Treatment for Type 2 Diabetes?
    Pratley, Richard E.
    DIABETES TECHNOLOGY & THERAPEUTICS, 2016, 18 (11) : 671 - 673
  • [22] The safety and tolerability of GLP-1 receptor agonists in the treatment of type 2 diabetes: a review
    Aroda, Vanita R.
    Ratner, Robert
    DIABETES-METABOLISM RESEARCH AND REVIEWS, 2011, 27 (06) : 528 - 542
  • [23] The safety and tolerability of GLP-1 receptor agonists in the treatment of type-2 diabetes
    Russell-Jones, D.
    INTERNATIONAL JOURNAL OF CLINICAL PRACTICE, 2010, 64 (10) : 1402 - 1414
  • [24] A comparison of currently available GLP-1 receptor agonists for the treatment of type 2 diabetes
    Montanya, Eduard
    EXPERT OPINION ON PHARMACOTHERAPY, 2012, 13 (10) : 1451 - 1467
  • [25] Treatment potential of the GLP-1 receptor agonists in type 2 diabetes mellitus: a review
    Ostergaard, L.
    Frandsen, Christian S.
    Madsbad, S.
    EXPERT REVIEW OF CLINICAL PHARMACOLOGY, 2016, 9 (02) : 241 - 265
  • [26] Treatment of Type 2 Diabetes With GLP-1 Receptor Agonists Among Patients With CKD
    Ostergaard, Jakob A.
    Cooper, Mark E.
    KIDNEY INTERNATIONAL REPORTS, 2022, 7 (11): : 2323 - 2324
  • [27] GLP-1 receptor agonists in the treatment of type 2 diabetes-state-of-the-art
    Nauck, Michael A.
    Quast, Daniel R.
    Wefers, Jakob
    Meier, Juris J.
    MOLECULAR METABOLISM, 2020, 46
  • [28] Effectiveness and Tolerability Profile of GLP-1 Receptor Agonists in Elderly Patients with Type 2 Diabetes
    Gorgojo-Martinez, Juan J.
    Feo-Ortega, Gara
    Serrano-Moreno, Clara
    Sanz-Velasco, Alberto
    DIABETES, 2016, 65 : A573 - A573
  • [29] Evaluating preferences for profiles of GLP-1 receptor agonists among injection-naive type 2 diabetes patients in the UK
    Gelhorn, Heather L.
    Poon, Jiat-Ling
    Davies, Evan W.
    Paczkowski, Rosirene
    Curtis, Sarah E.
    Boye, Kristina S.
    PATIENT PREFERENCE AND ADHERENCE, 2015, 9 : 1611 - 1622
  • [30] An overview of new GLP-1 receptor agonists for type 2 diabetes
    Tomlinson, Brian
    Hu, Miao
    Zhang, Yuzhen
    Chan, Paul
    Liu, Zhong-Min
    EXPERT OPINION ON INVESTIGATIONAL DRUGS, 2016, 25 (02) : 145 - 158
12345